Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Adds comments from CEO's letter and background throughout
Oct 21 (Reuters) -Catalent CTLT.N CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk NOVOb.CO.
Maselli's open letter comes on the back of criticism over Novo Holding's $16.5-billion acquisition of Catalent, which U.S. consumer groups said last week could threaten competition in weight-loss drugs and cutting-edge gene therapies. The groups have asked the U.S. Federal Trade Commission to block the deal.
Catalent is a manufacturing partner of Danish company Novo for Wegovy, its popular and highly effective weight-loss drug from the GLP-1 class which some analysts predict could become a $150 billion market by 2030. It also makes Sarepta Therapeutics' SRPT.O gene therapy Elevidys and others.
In response to the criticism, CEO Maselli reiterated in a letter to the company's customers that Catalent will continue to operate as an independent contract drugmaker.
"I want to be clear: our commitments to you will not change, your products will remain our focus and your proprietary information will be protected."
Maselli has been Catalent's CEO for over two years, and during his tenure the company conducted a strategic review as part of a settlement with activist investor Elliott Investment Management, which had been pushing for changes following manufacturing problems and declining revenue.
The deal with Novo Holding has secured approval from Brazil's antitrust regulator, but is awaiting clearances in Europe and the United States.
Earlier this month, U.S. Senator Elizabeth Warren also asked the Federal Trade Commision to closely scrutinize the acquisition, and block the deal if the regulator finds it illegal.
Catalent said on Monday it would continue to offer fill and finish services for sterile products for large and small molecules, including gene and cell therapies.
Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
